Serum concentrations of TNF-α and its soluble receptors in Graves’ disease
Open Access
- 1 July 2020
- journal article
- research article
- Published by Bioscientifica in Endocrine Connections
- Vol. 9 (7), 736-746
- https://doi.org/10.1530/ec-20-0162
Abstract
Graves' disease (GD), an organ-specific autoimmune disease, is the most common cause of hyperthyroidism. Tumour necrosis factor-alpha (TNF-α) exhibits immunological and metabolic activities involved in the induction and maintenance of immune responses. We attempted to evaluate the relationship between GD and serum TNF-α and its soluble receptors (sTNFRs), soluble tumour necrosis factor receptor 1 and 2 (sTNF-R1 and sTNF-R2). A total of 72 GD patients and 72 matched healthy individuals were recruited for this study. Serum TNF-α and sTNFRs were measured by sandwich ELISA. In our study, no significant difference was observed in TNF-α, but sTNFRs were found to be significantly elevated in GD patients compared to healthy individuals. Serum sTNFR levels were positively correlated with free triiodothyronine (FT3) and free thyroxine (FT4), and TNF-α was negatively correlated with thyroid-stimulating hormone (TSH) in the GD group. It was also shown that thyrotropin receptor antibody (TRAb) was positively correlated with TNF-α and sTNFRs. Spearman’s correlation analysis showed that only sTNF-R1 was positively correlated with complement C3. Multiple linear regression analysis suggests that serum levels of sTNF-R1 and FT4 may play an important role in the serum level of FT3. According to the median value of FT3 level, GD patients were further divided into a high FT3 group and a low FT3 group. The serum levels of sTNF-R1 in the high FT3 GD group were significantly higher than those in the low FT3 GD group. In conclusion, sTNFRs may play an important role in anti-inflammatory and immune response in GD.Keywords
This publication has 33 references indexed in Scilit:
- Impairment of Regulatory Capacity of CD4+CD25+ Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves’ DiseasePublished by The American Association of Immunologists ,2011
- Soluble Tumour Necrosis Factor-α Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves' DiseaseHormone and Metabolic Research, 2003
- TNF-R1 Signaling: A Beautiful PathwayScience, 2002
- Serum Th1 and Th2 Profile Cytokine Level Changes in Patients with Graves' Ophthalmopathy Treated with CorticosteroidsHormone and Metabolic Research, 2001
- Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' diseaseEuropean Journal of Immunology, 1997
- Cytokines and thyroid functionAdvances in Neuroimmunology, 1996
- Soluble receptors for tumour necrosis factor in clinical laboratory diagnosisEuropean Journal of Haematology, 1995
- Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL‐2) receptor (sIL‐2R) in thyroid diseasesClinical Endocrinology, 1992
- Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humansCytokine, 1990
- Volumetrie der Schilddrüsenlappen mittels Real-time-Sonographie* 1Deutsche Medizinische Wochenschrift (1946), 1981